Minerva Neurosciences (NERV) Depreciation & Amortization (CF) (2014 - 2025)
Minerva Neurosciences' (NERV) quarterly Depreciation & Amortization (CF) came in at $1360.0 in Q4 2025, little changed YoY from $1360.0 in Q4 2024, and little changed on a QoQ basis from $1361.0 in Q3 2025.
Powered by 
Analysis
Minerva Neurosciences (NERV) Depreciation & Amortization (CF) (2014 - 2025) Analysis & Trends
Minerva Neurosciences (NERV) has 10 years of Depreciation & Amortization (CF) data on file, last reported at $1360.0 in Q4 2025.
- Quarterly Depreciation & Amortization (CF) changed 0.0% year-over-year to $1360.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $4081.0 (down 25.02% YoY) and the FY2025 annual result came in at $5442.0, changed 0.0% from the prior year.
- Depreciation & Amortization (CF) steadied at $1360.0 in Q4 2025, from $1361.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $1361.0 in Q2 2023 to a low of $1360.0 in Q1 2023.
- A 3-year average of $1360.5 and a median of $1360.5 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The widest YoY moves for Depreciation & Amortization (CF): up 0.07% in 2024, down 0.07% in 2024.
- Tracing NERV's Depreciation & Amortization (CF) over 3 years: stood at $1361.0 in 2023, then decreased by 0.07% to $1360.0 in 2024, then changed by 0.0% to $1360.0 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $1360.0 (Q4 2025), $1361.0 (Q3 2025), and $1360.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1,360.00 |
| Sep 30, 2025 | 1,361.00 |
| Jun 30, 2025 | 1,360.00 |
| Mar 31, 2025 | 1,361.00 |
| Dec 31, 2024 | 1,360.00 |
| Sep 30, 2024 | 1,361.00 |
| Jun 30, 2024 | 1,361.00 |
| Mar 31, 2024 | 1,360.00 |
| Dec 31, 2023 | 1,361.00 |
| Sep 30, 2023 | 1,360.00 |
| Jun 30, 2023 | 1,361.00 |
| Mar 31, 2023 | 1,360.00 |
| Dec 31, 2020 | 2,911.00 |
| Sep 30, 2020 | 4,367.00 |
| Jun 30, 2020 | 4,366.00 |
| Mar 31, 2020 | 4,367.00 |
| Dec 31, 2019 | 4,367.00 |
| Sep 30, 2019 | 4,366.00 |
| Jun 30, 2019 | 4,367.00 |
| Mar 31, 2019 | 4,367.00 |